SCHEMBL4194693

SCHEMBL4194693

CCCCCCCCCCN1c2ccccc2S(=O)(=O)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.53
CDC25A P30304 1/20 0.53
RXFP1 Q9HBX9 1/20 0.51
LMNA P02545 3/20 0.50
TP53 P04637 2/20 0.50
ALDH1A1 P00352 1/20 0.50
ALDH2 P05091 1/20 0.50
ALDH3A1 P30838 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
HDAC3 O15379 1/20 0.49
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
HDAC4 P56524 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
HDAC1 Q13547 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10349326 1.00 CES1 (0.53) CES1CDC25ARXFP1LMNATP53
SCHEMBL32667803 1.00 CES1 (0.53) CES1CDC25ARXFP1LMNATP53
SCHEMBL14281166 0.86 RXFP1 (0.61) RXFP1LMNATP53POLBMAPT
SCHEMBL11182750 0.83 RXFP1 (0.51) RXFP1LMNATP53POLBMAPT
SCHEMBL3635173 0.82 CDC25A (0.61) CES1CDC25ALMNAALDH1A1ALDH2
SCHEMBL30141987 0.82 CDC25A (0.61) CES1CDC25ALMNAALDH1A1ALDH2
SCHEMBL15644072 0.80 ALDH1A1 (0.59) CES1CDC25ALMNATP53ALDH1A1
SCHEMBL1302641 0.79 LMNA (0.58) RXFP1LMNATP53ALDH1A1POLB
SCHEMBL4307189 0.78 RXFP1 (0.61) RXFP1LMNATP53ALDH1A1POLB
SCHEMBL30433630 0.78 RXFP1 (0.61) RXFP1LMNATP53ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090252895-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-10-08 US disclosed
US-20090041945-A1 ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-02-12 US disclosed
US-20080180501-A1 Actinic Ray Curable Composition, Actinic Ray Curable Ink, Image Forming Method Utilizing the Same, Ink-Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-07-31 US disclosed
US-7405308-B2 Thianthrenium salt cationic photoinitiators RENSSELAER POLYTECHNIC INSTITUE (US) 2008-07-29 US disclosed
US-7390840-B2 Active ray curable composition, active ray curable ink, image forming method and inkjet recording apparatus utilizing the same KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-06-24 US disclosed
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-05-08 US disclosed
US-7360883-B2 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-04-22 US disclosed
EP-1840148-A1 POLYMERIZABLE ACTINIC RADIATION CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTINIC RADIATION CURABLE INK AND IMAGE FORMATION METHOD, AND INK JET RECORDING APPARATUS AND EPOXY COMPOUND Konica Minolta Medical & Graphic, Inc. (JP) 2007-10-03 EP disclosed
EP-1837357-A1 ACTINIC RAY CURABLE COMPOSITION, ACTINIC RAY CURABLE INK, METHOD OF IMAGE FORMING THEREWITH, INKJET RECORDING APPARATUS AND EPOXY COMPOUND Konica Minolta Medical & Graphic, Inc. (JP) 2007-09-26 EP disclosed
EP-1829936-A1 ACTIVE RAY-CURABLE COMPOSITION, ACTIVE RAY-CURABLE INK AND IMAGE-FORMING METHOD Konica Minolta Medical & Graphic, Inc. (JP) 2007-09-05 EP disclosed
EP-1486526-B1 Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method KONICA MINOLTA MED & GRAPHIC (JP) 2006-08-16 EP disclosed
US-20060105111-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2006-05-18 US disclosed
US-20050215657-A1 Active ray curable composition, active ray curable ink, image forming method and inkjet recording apparatus utilizing the same KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2005-09-29 US disclosed
US-20050209365-A1 ink jet printing is disclosed, containing a compound represented by the following formula (a-1) or (a-2) and an alicyclic epoxy compound represented by the following formula (b). An image forming method by use thereof is also disclosed KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2005-09-22 US disclosed
US-20050190252-A1 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2005-09-01 US disclosed
US-20050064333-A1 Thianthrenium salt cationic photoinitiators RENSSELAER POLYTECHNIC INSTITUTE (US) 2005-03-24 US disclosed
EP-1504306-A1 PHOTOPOLYMERIZABLE COMPOSITIONS COMPRISING THIANTHRENIUM SALTS AS CATIONIC PHOTOINITIATORS RENSSELAER POLYTECHNIC INSTITUTE (US) 2005-02-09 EP disclosed
US-20040252171-A1 Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2004-12-16 US disclosed
EP-1486526-A1 Oxetane compound, actinic ray curable composition, ink composition for ink jet recording, and image formation method Konica Minolta Medical & Graphic, Inc. (JP) 2004-12-15 EP disclosed
WO-2003098347-A1 PHOTOPOLYMERIZABLE COMPOSITIONS COMPRISING THIANTHRENIUM SALT CATIONIC PHOTOINITIATORS RENSSELAER POLYTECHNIC INSTITUTE (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080180501-A1 Actinic Ray Curable Composition, Actinic Ray Curable Ink, Image Forming Method Utilizing the Same, Ink-Jet Recording Apparatus and Epoxy Compound ROCK1, MACF1, ACTN1 CES1 4319/4885CDC25A 2400/4885RXFP1 676/4885
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound CBR3, CBR1, CNR1 CES1 2969/4885CDC25A 2878/4885RXFP1 946/4885
US-20090041945-A1 ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS RIF1, NAP1L4, NAP1L1 CES1 4143/4885CDC25A 3193/4885RXFP1 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.